EU approves Amgen's bone drug Xgeva for cancer patients

07/18/2011 |

European regulators approved Amgen's Xgeva, or denosumab, for preventing fractures and other skeletal events in adults with solid tumors. The approval provides Amgen another year of market exclusivity. Denosumab also is marketed as Prolia for osteoporosis.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX